Legendary actor and filmmaker Mel Gibson revealed this week that he couldn't walk for months after taking the COVID vaccine.

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

Five years after the first cases of COVID-19, reports of hMPV, an obscure respiratory virus in China may understandably raise ...

If you don't know your blood type, you're not alone. However it is important medical information to know, and here's how you ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Respiratory illnesses are on the rise across San Antonio, Bexar County and Texas. Doctor Jason Bowling, a professor and infectious diseases specialist at UT Health San Antonio and the Chief ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individualsKavigale (sipavibart; AZD3152) is a ...